Julian Adams, Ph.D. President, Research and ­Development and Chief Scientific Officer, Infinity ­Pharmaceuticals Inc. Brent Ahrens. General Partner, Canaan Partners Kenneth C. Aldrich. CEO, Chairman, and Co-Founder, ­International Stem Cell Corp. Meryl Allison. Principal, Deloitte Consulting Karla Anderson. Managing Director, Pharmaceuticals and Life-Sciences, Advisory Services Group, PricewaterhouseCoopers Kelly Andrews. Director, Strategic Planning, MicroMass Sam Azoulay. Senior VP, Medical & Development, Emerging ­Markets Business Unit, Pfizer Inc. Jeff Baker. President and CEO, Noble ­Marketing Group Joseph Baron. Partner, Extera Partners Greg Barrett. VP of Marketing, Daiichi Sankyo Nancy Beesley. Executive VP, Client ­Services, HC&B Healthcare ­Communications Tim Bertram, D.V.M., Ph.D. Senior VP, Science and Technology, Tengion Wendy Blackburn. Executive VP, Intouch ­Solutions Chris Bode, Ph.D. VP, Corporate Development, ­Absorption ­Systems LP Paul Boni. Chief Research Officer, Grail Research Katrine Bosley. CEO, Avila Therapeutics Inc. Jesse Bowden. President, Imaging Services, Biomedical Systems Bonnie Brescia. Founding Principal, BBK Worldwide Patrick Brundage. Practice Leader, Enterprise ­Analytics ­Practice, Cognizant Carolyn Buck Luce. Global Pharmaceutical ­Leader, Ernst & Young Neil Campbell. Chairman and CEO, Mosaigen Faruk Capan. CEO, Intouch Solutions Jay Carter. Senior VP, Director of Client Services, ­AbelsonTaylor Bob Celeste. Director, GS1 Healthcare US Sam Chakraborty. Senior Director, SSA & Co. Michael N. Chang, Ph.D. President and CEO, Optimer ­Pharmaceuticals Inc. Tony Chant. Managing Director, Eurocom Healthcare ­Communications Dave Chapman. Managing Partner, ­CommonHealth Todd Clark. President, Value of Insight ­Consulting Inc. Patrick Collins. President, 5th Finger Nick Colucci. President and CEO, Publicis ­Healthcare ­Communications Group Terri Cooper, Ph.D. Principal, Deloitte ­Consulting LLP Ben Currie. Emerging Technologies, Purohit Navigation Lisa Davis. VP, Corporate Communications, AstraZeneca US Jim Dayton. Emerging Media Director, Intouch Solutions Evan Demesthas, M.D., R.PH. CEO, The Medical Affairs ­Company Phil Deschamps. CEO and President, GSW Worldwide Robert Dickinson. Client Service Officer, Life Sciences Practice, Grail Research Paul Dreyer. Chief Commercial Strategist, Friday ­Morning Matthew Eberhart. Global Business ­Development Leader, Quintiles Consulting Todd Everhart, M.D., FACP. Director, Medical Affairs, Americas, Chiltern Karen Ferrante, M.D. Senior VP, Clinical, ­Millennium: The ­Takeda Oncology Company Astrid Frank. General Manager, Fisher Clinical Services Laurie Halloran. President and CEO, Halloran ­Consulting Group Michael J. Harte. Founder and President, Harte Group Simon Higginbotham. Senior VP and Chief Marketing Officer, Kendle Terry Hisey. Vice ­Chairman and U.S. Industry Leader, Life ­Sciences Practice, Deloitte LLP Bill Hook. VP of Global Strategy, Healthcare ­Logistics, UPS Supply Chain Solutions A. Shabeer Hussain. Programme Leader, ­Pharmaceutical and ­Biotechnology, Healthcare, EIA, Frost & Sullivan Jason Hwang, M.D. Executive Director, ­Healthcare, Innosight Institute Jim Jenson, Ph.D. CEO, Dicerna Pharmaceuticals Jan-Anders Karlsson, Ph.D. CEO of S*BIO Pte Ltd. Liz Kay. VP, Account Service, Cramer Rick Keefer. President and CEO, Publicis ­Strategic ­Solutions Group Greg Kirsch. VP, Creative ­Services of Intouch Solutions Ryo Kubota, M.D., Ph.D. Chairman, President, and CEO, Acucela Michael J. Laferrera. Senior VP, Sales and ­Marketing, J. Knipper & Co. Inc. Nicholas Landekic. President and CEO, ­PolyMedix Inc. Ilyssa Levins. President and Founder, Center for ­Communication ­Compliance Kim Levy. Senior VP, MicroMass Communications Patrick Lindsay. Executive VP, United BioSource Corp. Nancy Lurker. CEO, PDI Inc. Alistair Macdonald. Executive VP, Global ­Services, INC Research John MacPhee. President, Strativa ­Pharmaceuticals John Maraganore, Ph.D. CEO, Alnylam ­Pharmaceuticals JeanMarie Markham. Founder and President, Clinlogix Inc. Rudiger Mees. CEO, Unithink David Merkel. Senior VP, Business Solutions, J. Knipper & Co. Inc. Sylvia Miriyam Findlay. Programme Leader, ­Pharmaceutical and Biotechnology, Healthcare, Europe, at Frost & Sullivan Celeste Mosby. VP, Life Sciences, Wilson Learning ­Worldwide Mike Myers. President, Palio Rajesh Nair, MMS, MBA. President and CEO, Indegene Peter Nalen. CEO, Compass Healthcare Communications Steven Nichtberger, M.D. President and CEO, Tengion Lance Nickens. President, The Patient Recruiting Agency Terry Nugent. VP Marketing, Medical ­Marketing Service Michael O’Connell. Director of Life Sciences, Tibco ­Spotfire Inc. Dave Ormesher. CEO, Closerlook Inc. Sanjay Parikh, Ph.D. Director, Indegene Stuart Peltz, Ph.D. CEO, PTC Therapeutics Adelene Perkins. President and Chief ­Business Officer, Infinity Pharmaceuticals Inc. Joseph Pieroni. President and CEO, Daiichi Sankyo Inc. Vinod Podichetty, M.D., MS. Chief Scientific Advisor, Research Practice Partners Inc. Richard F. Pops. Chairman, President, and CEO, Alkermes Inc. John Potthoff, Ph.D. Chief Operating Officer, INC Research Beth Price. Executive VP, The Medical Affairs ­Company Ahnal Purohit, Ph.D. President and CEO, Purohit ­Navigation Mark J. Pykett, V.M.D, MBA. President and Chief Operating ­Officer, Alseres Pharmaceuticals Louis Renzetti, Ph.D. VP and Global Head, RNA ­Therapeutics, Roche Ken Ribotsky. President and CEO, The Core Nation Inc. Rick Rosenthal. Principal and Practice Leader, Sales Force ­Effectiveness, Health ­Strategies Group Tom Russell. General Manager of ­Enterprise Solutions, SciQuest Inc. Mike Rutstein. Founder and President, StrikeForce ­Communications LLC Ed Sellers, M.D., Ph.D. VP, Early Stage, Kendle Bob Silvers. Managing Director, SSA & Co. Stephen M. Simes. President and CEO, BioSante ­Pharmaceuticals Raj Singh. VP, General Manager, Formedic Te Smith. VP, ­Communications,­ MarkMonitor Nagaraja Srivatsan. Head of Life Sciences, North ­America, ­Cognizant Technology Solutions Tom Steinke. CEO, Minnow Medical Inc. Mark Stejbach. VP and Chief ­Commercial Officer, Tengion Jeff Stomberg. CEO, Delta Pharma Jason Stowe. CEO, Cycle Computing Scott Treiber, Ph.D. Executive VP, Clinical ­Development Solutions, inVentiv Clinical Solutions Mark Weinstein. CEO, BioClinica Inc. James R. Weston. Senior VP, Talaris Advisors LLC Mike Wexler. Principal, Biltmore Technologies Roger L. Williams, M.D. CEO, U.S. Pharmacopeial Convention Dave Womelsdorf. Americas Advisory Leader, Life Sciences, Ernst & Young Steve Worland. President and CEO, Anadys ­Pharmaceuticals Donna Wray. Management Advisor, TGaS Advisors Steve Wunker. Senior Partner, Innosight Claire R. Wynters. Business Development Associate, ­ Criterium Inc. Kleanthis Xanthopoulos, Ph.D. President and CEO, Regulus ­Therapeutics Daniel Zurr, Ph.D. CEO and President, Quark ­Pharmaceuticals Inc. STATEMENT OF OWNERSHIP, MANAGEMENT, AND CIRCULATION 1. Publication title: PharmaVOICE 2. Publication no.: #23626 3. Filing date: September 28, 2009 4. Issue frequency: published monthly except combined issues in July/August and Nov./Dec. 5. No. of issues published annually: 10 6. Annual subscription price: US: $190. Non-US: $360. 7. Complete mailing address of known office of publication: Pharma­Linx LLC, 244 Jacobs Creek Road, Titusville, NJ 08560, Titusville, NJ 08560 8. Complete mailing address of headquarters or general business office of publisher: Pharma­Linx LLC, 244 Jacobs Creek Road, Titusville, NJ 08560, Titusville, NJ 08560 9. Full names and complete mailing addresses of publisher, editor, and ­managing editor: Lisa Banket, P.O. Box 327, Titusville, NJ 08560, Taren Grom, P.O. Box 327, Titusville, NJ 08560, and Denise Myshko, P.O. Box 327, Titusville, NJ 08560 10. Owner: Lisa Banket, Taren Grom, and Marah Walsh 11. Known bondholders, mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities: (none) 13. Publication title: PharmaVOICE 14. Issue date for circulation data below: September 2009 15. Extent and nature of circulation (avg. no. copies each issue during preceeding 12 months and actual no. copies of single issue published nearest to filing date, respectively). Total no. copies – 18,554 and 17,998. Individual paid/requested mail subscriptions stated on Form 3541: 16,558 and 16,014. Sales through dealers and carriers, street vendors, counter sales, and other paid or requested distribution outside USPS: 38 and 7. Total paid and/or requested ­circulation: 16,598 and 16,021. ­Nonrequested copies stated on Form 3541: 990 and 1,491. ­Non­requested copies distributed outside the mail: 588 and 127. Total ­nonrequested ­distribution: 1,578 and 1,618. Total ­distribution: 18,174 and 17,639. Copies not ­distributed: 380 and 359. Total: 18,554 and 17,998. Percent paid and/or requested ­circulation: 91.32 and 90.83. 16. This statement of ownership will be printed in the November/December 2009 issue of this ­publication. 17. I certify that all information furnished on this form is true and complete. I understand that ­anyone who furnishes false or misleading ­information on this form or who omits material or information on the form may be subject to criminal sanctions (including fines and ­imprisonment) and/or civil sanctions (including civil penalties). (Signed) Marah Walsh, Founding Partner

Download PDF